|Articles|March 1, 1996

Calcium Channel Blockers: 1995 -- The Year in Review
Volume 2
Issue 4 Suppl

Update - January 1996: FDA Does Not Support Labeling Changes to Calcium Antagonists Other Than Immediate-Release Nifedipine

Download PDF: Update - January 1996: FDA Does Not Support Labeling Changes to Calcium Antagonists Other Than Immediate-Release Nifedipine

Articles in this issue

over 30 years ago

Article

Calcium Channel Blockers: 1995 - An Overview

over 30 years ago

Article

Safety of Calcium Channel Blockers: Results of Recent Trials

over 30 years ago

Article

Calcium Channel Blockers: New Trials and Trials in Progress

over 30 years ago

Article

Are Calcium Channel Blockers Prohemorrhagic?

over 30 years ago

Article

A Provocative Interpretation of the Case Control Analysis

over 30 years ago

Article

Shades of Opinion: What Is Prudent?

over 30 years ago

Article

Participants

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Update - January 1996: FDA Does Not Support Labeling Changes to Calcium Antagonists Other Than Immediate-Release Nifedipine

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial

5 Things to Know About the FDA's Peptide Reversal

Iberdomide Complements CAR T in Myeloma: Swarup Kimar, MD

Contributor: The Deadly Gap in the Charity Care System

Complementary, Not Competing: How an Endocrinologist Compares Dual Incretin Approaches for Obesity and MASH